PRAX Filings — Praxis Precision Medicines, Inc. - FilingSpy
PRAX
Praxis Precision Medicines, Inc.
A biopharmaceutical company developing treatments for brain disorders like epilepsy and essential tremor, using two platforms—Cerebrum for small-molecule drugs and Solidus for antisense oligonucleotide therapies. Its lead candidates include ulixacaltamide for essential tremor and seizure-fighting drugs like relutrigine. Founded in 2015 as EpiPM Therapeutics, it took its name from the Greek "praxis," meaning "to do"—turning scientific theory into practical treatment.
Net loss widened to $83.7M as Praxis builds commercial infrastructure ahead of two FDA drug reviews, supported by a $1.4B cash position.
Praxis is no longer just an R&D story — it is now spending to become a commercial company. Net loss widened to $83.7 million from $71.1 million a year ago, as general and administrative costs more than doubled to $27.9 million to prepare for potential drug launches, while R&D expense rose 28% to $78.0 million. The company has $1.4 billion in cash to see it through two FDA decisions, but the spending is now shifting from the lab to the market.
Key takeaways
General and administrative expense more than doubled to $27.9 million from $11.6 million a year ago, driven by a $9.8 million increase in personnel-related costs and a $3.5 million rise in professional fees as the company builds commercial capabilities ahead of potential ulixacaltamide and relutrigine launches.
R&D expense rose 28% to $78.0 million, with Cerebrum platform spending up $9.2 million on relutrigine and vormatrigine, partially offset by lower ulixacaltamide costs following its submission.
Section summaries
Management's Discussion and Analysis
Net loss widened to $176.3M in H1 2026 as R&D and pre-commercial G&A spending rose, offset by $1.4B cash runway into 2028.
⌄
Total operating expenses rose $52.0M to $202.8M for H1 2026, driven by a $28.4M increase in G&A for pre-launch commercial preparations and a $23.6M increase in R&D.
Cash, equivalents, and marketable securities reached $1.4 billion at quarter-end, up from $926.1 million at year-end 2025, after the company raised $621.2 million in net proceeds from a January 2026 follow-on public offering.
Operating cash outflow was $77.5 million for the quarter, up from $54.7 million a year earlier, reflecting the higher spending across both R&D and pre-commercial activities.
Management expects the current cash position to fund operations into 2028, and the company reported no material changes to its risk factors or legal proceedings.
What changed
The ulixacaltamide and relutrigine NDAs flagged as the central catalysts in the FY 2025 10-K have been submitted to the FDA, and the company is now spending on pre-launch commercial preparations rather than the clinical trials themselves.
The elsunersen Phase 2/3 EMBRAVE study topline data, expected in the first half of 2026, was not reported in this filing.
The cash position swelled to $1.4 billion after the January 2026 offering, extending the runway into 2028 and marking a shift from the prior pattern of raising funds to support R&D to raising funds to support a commercial launch.
G&A expense has become a material driver of the cost structure, rising to $27.9 million in Q2 2026 from $13.9 million in Q1 2025, as the company transitions from a purely clinical-stage organization.
What to watch
FDA acceptance and review timelines for the ulixacaltamide and relutrigine NDAs, including any advisory committee meetings or requests for additional data.
Topline data from the elsunersen Phase 2/3 EMBRAVE study in SCN2A gain-of-function DEE, expected in the first half of 2026.
Quarterly G&A expense trajectory as the company builds commercial infrastructure, and whether the cash burn rate accelerates beyond the R&D-driven pace of prior quarters.
Progress of the vormatrigine registrational POWER1 and POWER2 studies for focal onset seizures, and any interim data readouts.
R&D expense grew to $147.4M in H1 2026, primarily from a $9.7M increase in Solidus™ platform costs including a $5.0M milestone to Ionis, and an $8.2M rise in personnel-related costs.
Cerebrum™ platform R&D was nearly flat at $92.4M in H1 2026, as a $13.0M decrease in ulixacaltamide spend was offset by a $7.6M increase for relutrigine and $5.9M for earlier-stage assets.
G&A expense jumped $28.4M to $55.4M in H1 2026, mainly from a $15.5M increase in personnel costs and an $11.3M rise in professional fees for potential ulixacaltamide and relutrigine launches.
Cash, equivalents, and marketable securities totaled $1.4B as of June 30, 2026, expected to fund operations into 2028, supported by $621.2M in net proceeds from a January 2026 public offering.
Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because cash, cash equivalents and marketable securities w…
⌄
We are exposed to market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because cash, cash equivalents and marketable securities we may hold at any time may be in the form of money market funds or marketable debt securities or may be invested in U.S. Treasury and U.S. government agency obligations.
29
However, because of the low risk profile of the instruments in our portfolio at any given time, an immediate change in market interest rates of 100 basis points would not have a material impact on our financial position or results of operations.
As of the date of this Quarterly Report on Form 10-Q, we are not party to any material legal matters or claims. We may become party to legal matters and claims arising in the ordinary course of business. We cannot predict the outcome of any such legal matters or claims, and desp…
⌄
As of the date of this Quarterly Report on Form 10-Q, we are not party to any material legal matters or claims. We may become party to legal matters and claims arising in the ordinary course of business. We cannot predict the outcome of any such legal matters or claims, and despite the potential outcomes, the existence thereof may have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
There have been no material changes from the risk factors previously disclosed in the section entitled "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 19, 2026.
⌄
There have been no material changes from the risk factors previously disclosed in the section entitled "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 19, 2026.